**
Palantir Technologies, a prominent US data analytics firm, is making headlines as it plays a pivotal role in the NHS’s ambitious £330 million Federated Data Platform. Advocates tout its potential for enhancing healthcare efficiency, while critics voice serious concerns regarding privacy, transparency, and governance. Here’s a deep dive into what Palantir does and why its involvement with the NHS is generating such a passionate response.
What is Palantir?
Palantir is a heavyweight in the tech world, known for its prowess in managing vast datasets and providing analytical tools that leverage artificial intelligence. Its flagship platform, Foundry, is utilised by various organisations, including government bodies and large corporations, to uncover insights, streamline operations, and bolster decision-making processes. The company’s chairman, Peter Thiel, is no stranger to controversy; his views on the NHS and its perceived inefficiencies have sparked significant debate, particularly his assertion that the NHS should be privatised.
The Role of a Private Firm in Public Health
The involvement of Palantir in NHS operations raises the question: why is a private American company managing sensitive medical records? Palantir positions itself as a facilitator, offering a platform for the NHS to securely store and analyse its data. This is not an uncommon practice; many public entities rely on cloud services from major American tech firms. However, the trustworthiness of Palantir compared to giants like Microsoft or Amazon is a point of contention among stakeholders.
The Contracting Controversy
Palantir secured its NHS contracts under the governments of Boris Johnson in 2020 and Rishi Sunak in 2023, initially lobbying for access to NHS data by proposing to create a COVID data store for just £1. This arrangement bypassed standard competitive bidding processes due to emergency procurement rules established during the pandemic. The original contract was only disclosed after legal pressure, and subsequent renewals have faced scrutiny over their lack of transparency. The most recent deal, awarded in December 2023 to a consortium led by Palantir, has raised further questions about potential “vendor lock-in”—a situation where an organisation becomes dependent on a single supplier.
Data Use and Privacy Concerns
Many people are understandably worried about the implications of Palantir’s data handling. As a “data processor,” Palantir is restricted from making independent decisions regarding NHS data; that authority lies solely with NHS organisations. Despite assurances of compliance with data protection regulations, the ambiguity surrounding what Palantir can legitimately do with NHS data, especially regarding AI model training, fuels scepticism. Notably, much of the data protection language in the latest contract remains redacted, further complicating the public’s understanding of the agreement.
Concerns about data privacy are magnified by the fact that the US has laws, such as the Cloud Act, which could allow American authorities to access data stored by US-based companies. This raises alarms among privacy advocates who fear potential cross-border data sharing.
The Federated Data Platform: A Step Forward or a Risk?
The Federated Data Platform represents a long-standing ambition of NHS England to centralise all NHS data. Initially birthed from the NHS COVID-19 Data Store, this platform aims to improve health service planning and operational efficiency. However, sceptics question whether the expected benefits justify the investment, as researchers have expressed doubts regarding the methods used to measure success.
The Wider Implications of Palantir’s Involvement
Palantir’s history, including initial funding from In-Q-Tel, the CIA’s venture capital arm, and its work with controversial entities such as the US Immigration and Customs Enforcement (ICE), only adds to the distrust surrounding its partnership with the NHS. Concerns about the ethical implications of its involvement in healthcare are voiced by many within the medical community, who worry about the concentration of sensitive data processing within a single supplier.
Can Patients Opt-Out?
Patients do have the option to prevent their GP practices from sharing their health data, but opting out can have unintended consequences. Such decisions may hinder beneficial uses of health data, leading to a less comprehensive dataset that could affect healthcare outcomes. This raises serious ethical questions about the impact of individual choices on broader public health initiatives.
Opposition from Healthcare Professionals
Various healthcare professionals, campaigners, and members of the public have expressed their opposition to Palantir’s role in the NHS. Their concerns stem from both the company’s political stance and its controversial operations. The fear is that this partnership might not only compromise patient trust but could also potentially degrade the quality of healthcare services.
The Future of the Contract
The current contract with Palantir includes a break clause, allowing the government to terminate it if necessary. Should this happen, Palantir is required to relinquish all access to NHS data. Louis Mosley, Palantir’s UK executive vice-chair, has defended the company, asserting that it prioritises patient data security and is committed to delivering value for the NHS.
Why it Matters
Palantir’s integration into the NHS highlights a crucial intersection between technology and public health, raising essential questions about data privacy, corporate influence, and the ethical responsibilities of tech companies in managing sensitive information. As the NHS navigates this complex partnership, the outcomes will not only shape the future of healthcare delivery in the UK but also set precedents for how private firms interact with public health systems worldwide. The implications for patient trust, data security, and the integrity of healthcare services are profound, making it imperative for all stakeholders to engage in a transparent and informed dialogue about the role of technology in health.
